132 related articles for article (PubMed ID: 3530447)
1. Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial.
Gockerman JP; Spremulli EN; Raney M; Logan T
Cancer Treat Rep; 1986 Oct; 70(10):1199-203. PubMed ID: 3530447
[TBL] [Abstract][Full Text] [Related]
2. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women.
Mouridsen HT; Salimtschik M; Dombernowsky P; Gelshoj K; Palshof T; Rorth M; Daehnfeldt JL; Rose C
Eur J Cancer (1965); 1980; Suppl 1():107-10. PubMed ID: 7032918
[No Abstract] [Full Text] [Related]
4. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
[TBL] [Abstract][Full Text] [Related]
6. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
[TBL] [Abstract][Full Text] [Related]
7. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer.
Beex L; Pieters G; Smals A; Koenders A; Benraad T; Kloppenborg P
Cancer Treat Rep; 1981; 65(3-4):179-85. PubMed ID: 7237448
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
10. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
11. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
[TBL] [Abstract][Full Text] [Related]
12. Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer.
Krook JE; Ingle JN; Green SJ; Bowman WD; Everson LK; Windschitl HE; Marschke RF; Laurie JA; Cullinan SA; Pfeifle DM
Cancer Treat Rep; 1985 Apr; 69(4):355-61. PubMed ID: 3888386
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
Ansari TN; Mahmood A; Hussain I; Samad A
J Coll Physicians Surg Pak; 2005 Apr; 15(4):204-6. PubMed ID: 15857590
[TBL] [Abstract][Full Text] [Related]
14. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
[TBL] [Abstract][Full Text] [Related]
15. DES versus tamoxifen in advanced breast cancer.
N Engl J Med; 1981 Apr; 304(17):1041-3. PubMed ID: 7010171
[No Abstract] [Full Text] [Related]
16. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogen treatment of breast cancer: an overview.
Pearson OH; Manni A; Arafah BM
Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
[TBL] [Abstract][Full Text] [Related]
18. Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).
Ciocca DR; Green S; Elledge RM; Clark GM; Pugh R; Ravdin P; Lew D; Martino S; Osborne CK
Clin Cancer Res; 1998 May; 4(5):1263-6. PubMed ID: 9607585
[TBL] [Abstract][Full Text] [Related]
19. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
20. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
Mauriac L; Durand M; Bonichon F; Chauvergne J
Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
